Nearly 780 people die every day in Europe from liver diseaseāa largely preventable crisis.
A new report from the EASLāLancet Commission calls for urgent policy action to tackle Europeās rising liver disease burden: spkl.io/63326AfOqr
Find out how #lipid #metabolism plays a role in #drugresistance in #lungcancer in our new study from the PhD work of Julia Babuta and collaboration with AstraZeneca!
pubs.acs.org/doi/full/10....
#ReviewšØ
Metabolic dysfunction associated steatotic liver disease #MASLD and alcoholic liver disease #ALD drive liver cancer. HeikenwƤlder&Co review mechanisms of disease progression and therapeutic advances to reduce cancer risk.
šš
Nonsmall-cell lung cancer (NSCLC) accounts for more than 80% of lung cancer cases. Epidermal growth factor receptor mutations (EGFRm) occur in 15 and 40% of NSCLC in Western and Asian populations, res...
Metabolic dysfunction-associated steatotic liver disease (MASLD) and alcoholic liver disease (ALD) are drivers of liver cancer, promoting its development through chronic liver injury and inflammation. In this Review, Rahbari et al. highlight the distinct pathophysiological mechanisms of progression and therapeutic advancements for MASLD and ALD, emphasizing the need for more tailored approaches to manage these complex diseases and their cancer risks.
dlvr.it
Congratulations to the whole team - happy that @gruevska.bsky.social and I could play a small part in this exciting study!
